By DEE-ANN DURBIN

AP – Beyond Meat and Impossible Foods found success with realistic plant-based burgers. Now, they’re hoping to replicate that in the fast-growing but crowded market for plant-based chicken nuggets.

Beyond Meat said Monday that its new tenders, made from fava beans, will go on sale in U.S. groceries in October. Walmart, Jewel-Osco and Harris Teeter will be among the first to offer them.

Impossible Foods began selling its soy-based nuggets this month at Walmart, Kroger, Albertsons and other groceries. They’ll be in 10,000 stores by later this year.

The rival startups, both based in California, helped redefine what plant-based burgers could be. Beyond burgers were the first to be sold in grocery aisles next to conventional meat in 2016; Impossible burgers joined them a few years later.

But this time, Beyond and Impossible will be stacked in freezers already bursting with plant-based chicken options. More than 50 brands of plant-based nuggets, tenders and cutlets are already on sale in U.S. stores, according to the Good Food Institute, which tracks plant-based brands.

Some, like Morningstar Farms and Quorn, have been making plant-based meat for decades. But Beyond and Impossible have also spawned a host of imitators making realistic products marketed to omnivores, not just vegans and vegetarians. Fifteen percent of those 50 brands were new to the U.S. market in 2020, like Nuggs, from New York startup Simulate, and California’s Daring Foods.

They’re all trying to grab a slice of the plant-based market, which is still dwarfed by the conventional meat market but growing fast. U.S. sales of frozen, plant-based chicken tenders and nuggets jumped 29% to $112 million in the 52 weeks ending Aug. 28, according to Nielsen IQ. Sales of conventional frozen tenders and nuggets rose 17% to $1.1 billion in the same period.

Globally, retail sales of meat substitutes are expected to grow 2% to 4.6 million metric tons between 2021 and 2022, according to the market research firm Euromonitor. Processed animal meat sales are expected to stay flat in the same period, at 18.9 million metric tons.

Tom Rees, an industry manager with Euromonitor, said plant-based meat sales were already growing before the coronavirus hit. In Euromonitor surveys, nearly a quarter of consumers worldwide say they are limiting meat intake for health reasons.

But the pandemic gave plant-based meat a boost as consumers looked for new things to cook at home. Rees said meat shortages and coronavirus outbreaks at meat production facilities also made consumers think twice about the animal meat market.

Meat or no meat, breaded nuggets aren’t exactly a health food. One serving of Beyond’s chicken tenders have 12 grams of fat, 450 milligrams of sodium, 11 grams of protein and 210 calories. Impossible’s nuggets have 10 grams of fat, 320 milligrams of sodium, 10 grams of protein and 200 calories. By comparison, a similar size serving of Pilgrim’s chicken nuggets contains 14 grams of fat, 10 grams of protein, 460 milligrams of sodium and 220 calories.

Impossible Foods Vice President of Product Innovation Celeste Holz-Schietinger said it was important to start with plant-based burgers because beef production is a bigger contributor to climate change. But Impossible spent the past year developing the plant-based tenders as part of a goal is to replace all animal agriculture with more sustainable alternatives by 2035.

Beyond Meat has been experimenting with chicken for even longer. The El Segundo, California-based company launched chicken strips in 2012. But it pulled them from the market in 2019, citing the need to devote more manufacturing capacity to its burgers.

Unlike the new fava bean-based tenders, Beyond’s burgers are made with pea protein. Beyond President and CEO Ethan Brown said the company has spent more than a decade researching various protein sources and their attributes and doesn’t want to limit itself to just one.

Dariush Ajami, Beyond’s chief innovation officer, said mimicking the fibrous texture and fat distribution in chicken was the biggest challenge with the new tenders. The company is still far from perfecting a plant-based chicken breast or a marbled steak, but has 200 scientists and engineers working on it, he said.

“The goal is to reduce that gap between our product and animal meat,” he said.

There’s also a price gap. Beyond Meat’s suggested retail price for an 8-ounce package is $4.99, while Impossible’s 13.5-ounce package costs $7.99. Tyson Foods sells a 2-pound bag of chicken nuggets at Walmart for $5.76.

But it’s clear many people are eager to try plant-based foods. In July, Panda Express quickly sold out of Beyond Meat orange chicken in a trial run at locations in Los Angeles and New York. Panda Express says it’s exploring a wider rollout of the product, which was specially developed for the brand.

Jasmine Alkire recently tried Beyond Meat orange chicken at a Panda Express in Los Angeles. Alkire became a vegetarian seven years ago, but the Beyond chicken tasted similar to the orange chicken she grew up eating.

“It was flavorful and didn’t have a weird aftertaste or off-putting texture,” she said.

For now, Beyond Meat has several advantages. It has partnerships with big brands like KFC and McDonald’s and has already opened its first manufacturing plant in China, where Impossible’s products aren’t yet sold.

Impossible is still waiting for regulatory approval to sell its burgers in Europe and China because they contain genetically modified ingredients. But Impossible’s chicken doesn’t contain those same ingredients. Both companies plan to sell their chicken overseas.

Impossible is confident that consumers will gravitate to its nuggets. In company taste tests, it found that most consumers preferred its product to actual chicken.

“It’s better for you, its better for the environment and it tastes better than the animal,” said Impossible Foods President Dennis Woodside. “So we think that’s a pretty strong value proposition.”

Other brands insist they’ll defend their turf. Morningstar Farms, the current plant-based poultry sales leader in the U.S., launched a separate brand called Incogmeato in 2019 with products that closely replicate meat.

Sara Young, the general manager of plant-based proteins at Kellogg Co., which owns Morningstar, said the brand has the biggest product portfolio and the highest repeat-buyer rate in the plant-based category.

“We’ve been at this for a long time,” she said.

___

Terence Chea contributed from Redwood City, California.

By LAURAN NEERGAARD and MIKE STOBBE

AP – The Centers for Disease Control and Prevention on Thursday endorsed booster shots for millions of older or otherwise vulnerable Americans, opening a major new phase in the U.S vaccination drive against COVID-19.

CDC Director Dr. Rochelle Walensky signed off on a series of recommendations from a panel of advisers late Thursday.

The advisers said boosters should be offered to people 65 and older, nursing home residents and those ages 50 to 64 who have risky underlying health problems. The extra dose would be given once they are at least six months past their last Pfizer shot.

However, Walensky decided to make one recommendation that the panel had rejected.

The panel on Thursday voted against saying that people can get a booster if they are ages 18 to 64 years and are health-care workers or have another job that puts them at increased risk of being exposed to the virus.

But Walensky disagreed and put that recommendation back in, noting that such a move aligns with an FDA booster authorization decision earlier this week. The category she included covers people who live in institutional settings that increase their risk of exposure, such as prisons or homeless shelters, as well as health care workers.

The panel had offered the option of a booster for those ages 18 to 49 who have chronic health problems and want one. But the advisers refused to go further and open boosters to otherwise healthy front-line health care workers who aren’t at risk of severe illness but want to avoid even a mild infection.

The panel voted 9 to 6 to reject that proposal. But Walensky decided to disregard the advisory committee’s counsel on that issue. In a decision several hours after the panel adjourned, Walensky issued a statement saying she had restored the recommendation.

“As CDC Director, it is my job to recognize where our actions can have the greatest impact,” Walensky said in a statement late Thursday night. “At CDC, we are tasked with analyzing complex, often imperfect data to make concrete recommendations that optimize health. In a pandemic, even with uncertainty, we must take actions that we anticipate will do the greatest good.”

Experts say getting the unvaccinated their first shots remains the top priority, and the panel wrestled with whether the booster debate was distracting from that goal.

All three of the COVID-19 vaccines used in the U.S. are still highly protective against severe illness, hospitalization and death, even with the spread of the extra-contagious delta variant. But only about 182 million Americans are fully vaccinated, or just 55% of the population.

“We can give boosters to people, but that’s not really the answer to this pandemic,” said Dr. Helen Keipp Talbot of Vanderbilt University. “Hospitals are full because people are not vaccinated. We are declining care to people who deserve care because we are full of unvaccinated COVID-positive patients.”

Thursday’s decision represented a dramatic scaling back of the Biden administration plan announced last month to dispense boosters to nearly everyone to shore up their protection. Late Wednesday, the Food and Drug Administration, like the CDC panel, signed off on Pfizer boosters for a much narrower slice of the population than the White House envisioned.

The booster plan marks an important shift in the nation’s vaccination drive. Britain and Israel are already giving a third round of shots over strong objections from the World Health Organization that poor countries don’t have enough for their initial doses.

Walensky opened Thursday’s meeting by stressing that vaccinating the unvaccinated remains the top goal “here in America and around the world.”

Walensky acknowledged that the data on who really needs a booster right away “are not perfect.” “Yet collectively they form a picture for us,” she said, “and they are what we have in this moment to make a decision about the next stage in this pandemic.”

The CDC panel stressed that its recommendations will be changed if new evidence shows more people need a booster.

The CDC advisers expressed concern over the millions of Americans who received Moderna or Johnson & Johnson shots early in the vaccine rollout. The government still hasn’t considered boosters for those brands and has no data on whether it is safe or effective to mix-and-match and give those people a Pfizer shot.

“I just don’t understand how later this afternoon we can say to people 65 and older, ‘You’re at risk for severe illness and death, but only half of you can protect yourselves right now,’” said Dr. Sarah Long of Drexel University.

About 26 million Americans got their last Pfizer dose at least six months ago, about half of whom are 65 or older. It’s not clear how many more would meet the CDC panel’s booster qualifications.

CDC data show the vaccines still offer strong protection against serious illness for all ages, but there is a slight drop among the oldest adults. And immunity against milder infection appears to be waning months after people’s initial immunization.

For most people, if you’re not in a group recommended for a booster, “it’s really because we think you’re well-protected,” said Dr. Matthew Daley of Kaiser Permanente Colorado.

Public health experts not involved in Thursday’s decision said it is unlikely people seeking third doses at a drugstore or other site will be required to prove they qualify.

Even with the introduction of boosters, someone who has gotten just the first two doses would still be considered fully vaccinated, according to the CDC’s Dr. Kathleen Dooling. That is an important question to people in parts of the country where you need to show proof of vaccination to eat in a restaurant or enter other places of business.

Among people who stand to benefit from a booster, there are few risks, the CDC concluded. Serious side effects from the first two Pfizer doses are exceedingly rare, including heart inflammation that sometimes occurs in younger men. Data from Israel, which has given nearly 3 million people — mostly 60 and older — a third Pfizer dose, has uncovered no red flags.

The U.S. has already authorized third doses of the Pfizer and Moderna vaccines for certain people with weakened immune systems, such as cancer patients and transplant recipients. Other Americans, healthy or not, have managed to get boosters, in some cases simply by asking.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.